Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Post by cool888on Jun 21, 2022 5:13pm
252 Views
Post# 34772380

More vulnerable people receiving fewer COVID pills !

More vulnerable people receiving fewer COVID pills !#Bucillamine - The World need this one very, very soon !!

June 21 (Reuters) - People in socially and economically disadvantaged regions are about half as likely to receive an oral antiviral COVID-19 pill than residents of wealthier zip codes, according to a U.S. government study published on Tuesday.

The findings by the U.S. Centers for Disease Control and Prevention (CDC) revealed this disparity even as there were more dispensing sites located in high-vulnerability U.S. zip codes than in the more advantaged areas.

The CDC study comes amid government efforts in recent months to boost access to the treatments from Pfizer and Merck.

CDC researchers analysed data from Dec. 23, 2021 to May 21, 2022 when more than 1 million oral antiviral prescriptions were dispensed in the United States, with most of the drugs given out between March and May.

 

The findings underscore an ongoing need to identify and eliminate barriers to oral antiviral access, the agency said.

Federal efforts to expand access to the treatments include the "Test to Treat" initiative that allows Americans to get tested for COVID-19 at a pharmacy and receive free pills if they test positive.

(Reporting by Amruta Khandekar in Bengaluru; Editing by Vinay Dwivedi)






<< Previous
Bullboard Posts
Next >>